Cite
HARVARD Citation
Spigel, D. et al. (2018). Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures. Cancer. 124 (11), pp. 2355-2364. [Online].